WO2022254377 - NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES
National phase entry:
Publication Number
WO/2022/254377
Publication Date
08.12.2022
International Application No.
PCT/IB2022/055168
International Filing Date
02.06.2022
Title **
[English]
NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES
[French]
CONJUGUÉS NÉODÉGRADEUR-ANTICORPS ANTI-CD33
Applicants **
ORUM THERAPEUTICS, INC.
2F, 281-25, Munji-ro
Yuseong-gu, Daejeon
34050, KR
BRISTOL-MYERS SQUIBB COMPANY
Route 206 & Province Line Road
Lawrenceville, NJ 08540, US
Inventors
FISHKIN, Nathan
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
PARK, Peter U.
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
BAI, Chen
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
Priority Data
63/202,272
03.06.2021
US
63/282,588
23.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3441 | |
| EPO | Filing, Examination | 29676 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 14810 |
Total: 49129 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides neoDegraders conjugated to anti-CD33 antibodies. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.[French]
La présente invention concerne des conjugués néoDégradeur-anticorps anti-CD33. L'invention concerne également des compositions comprenant les conjugués. Les composés et les compositions sont utiles pour traiter une maladie ou un état, par exemple, un cancer, chez un sujet en ayant besoin.